Last reviewed · How we verify
RXI-109
At a glance
| Generic name | RXI-109 |
|---|---|
| Sponsor | RXi Pharmaceuticals, Corp. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD (PHASE1, PHASE2)
- A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Revised Hypertrophic Scars (PHASE2)
- A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery in Healthy Adults (PHASE2)
- A Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults (PHASE2)
- Evaluation of Safety, PK, and Preliminary Effects on Scar Formation of Multiple Intradermal Administrations of RXI-109 (PHASE1)
- Evaluation of the Safety, Pharmacokinetics, and Preliminary Effect on Scar Formation by RXI-109 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RXI-109 CI brief — competitive landscape report
- RXI-109 updates RSS · CI watch RSS
- RXi Pharmaceuticals, Corp. portfolio CI